Inhaled drug treatment for tuberculosis: Past progress and future prospects

AJ Hickey, PG Durham, A Dharmadhikari… - Journal of Controlled …, 2016 - Elsevier
Since the 1990s the rising incidence of multiple drug resistant TB, particularly in the context
of human immunodeficiency virus co-infected patients, has threatened global TB control. At …

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

MS Miranda, MT Rodrigues, RMA Domingues… - Materials Science and …, 2018 - Elsevier
The growing interest on polymeric delivery systems for pulmonary administration of drugs
anticipates a more direct and efficient treatment of diseases such as tuberculosis (TB) that …

Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages

RS Rekha, SSVJ Rao Muvva, M Wan, R Raqib… - Autophagy, 2015 - Taylor & Francis
LL-37 is a human antimicrobial peptide (AMP) of the cathelicidin family with multiple
activities including a mediator of vitamin D-induced autophagy in human macrophages …

Dynamic mucus penetrating microspheres for efficient pulmonary delivery and enhanced efficacy of host defence peptide (HDP) in experimental tuberculosis

A Sharma, K Vaghasiya, P Gupta, AK Singh… - Journal of controlled …, 2020 - Elsevier
Pulmonary drug delivery system is increasingly gaining popularity for several lung diseases
including tuberculosis (TB) due to its ability to attain high drug concentrations at the site of …

Inhalable Particles Containing Rapamycin for Induction of Autophagy in Macrophages Infected with Mycobacterium tuberculosis

A Gupta, G Pant, K Mitra, J Madan… - Molecular …, 2014 - ACS Publications
We investigated whether particles suitable for delivery to alveolar macrophages may provide
a means of targeting rapamycin, an inducer of autophagy, to alveolar macrophages as a …

Targeted Pulmonary Delivery of the Green Tea Polyphenol Epigallocatechin Gallate Controls the Growth of Mycobacterium tuberculosis by Enhancing the Autophagy …

A Sharma, K Vaghasiya, E Ray, P Gupta… - ACS Biomaterials …, 2020 - ACS Publications
Growing rates of tuberculosis (TB) superbugs are alarming, which has hampered the
progress made to-date to control this infectious disease, and new drug candidates are few …

THP-1 cell line model for tuberculosis: a platform for in vitro macrophage manipulation

PT Shah, M Tufail, C Wu, L **ng - Tuberculosis, 2022 - Elsevier
Macrophages are large mononuclear phagocytic cells that play a vital role in the immune
response. They are present in all body tissues with extremely heterogeneous and plastic …

Emerging and alternative strategies for the treatment of nontuberculous mycobacterial infections

A Sreekumar, A Kumar, R Biswas… - Expert Review of Anti …, 2024 - Taylor & Francis
Introduction Nontuberculous mycobacteria (NTM) infections have emerged as a significant
clinical challenge due to their intrinsic multidrug resistance and the limited efficacy of …

Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis

AJ Hickey, A Misra, PB Fourie - Journal of pharmaceutical sciences, 2013 - Elsevier
Inhaled therapies offer a unique approach to the treatment of tuberculosis (TB) using a
relevant target organ system as a route of administration. The number of research reports on …

Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month

AK Singh, RK Verma, JK Mukker, AB Yadav, P Muttil… - Tuberculosis, 2021 - Elsevier
We investigated the preclinical efficacy and safety/tolerability of biodegradable polymeric
particles containing isoniazid (INH) and rifabutin (RFB) dry powder for inhalation (DPI) as an …